What type of study is this?

December 8, 2025BloodOpen Access

Clinical outcomes in patients with accelerated or blast-Phase MPN treated with triplet regimen of hypomethylating agent, JAK inhibitor, and venetoclax (HMA/JAKi/Ven): A multicenter case series

View Full Paper

Ask AI

Bookmark

Authors

EREllen K. RitchieCornell University

Discussion

Member takes

Implication

Retrospective case series demonstrates triplet regimen with HMA, JAKi, and venetoclax offers modest outcomes in myeloproliferative neoplasm patients, suggesting further investigation is needed.

Key Points

The treatment yielded an overall response rate of 55% among patients diagnosed with myeloproliferative neoplasm.
Patients who responded had a median overall survival of 15.8 months, outperforming non-responders significantly.
This retrospective case series spanned patients treated at two major cancer centers from 2020 to 2024.
Identifying unique mutational landscapes in responders may help predict who benefits from the triplet therapy.

Cite This Study

Ellen K. Ritchie (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d7a7 https://doi.org/10.1182/blood-2025-2026

View Full Paper

Ask AI

Bookmark

Implication

Retrospective case series demonstrates triplet regimen with HMA, JAKi, and venetoclax offers modest outcomes in myeloproliferative neoplasm patients, suggesting further investigation is needed.

Clinical outcomes in patients with accelerated or blast-Phase MPN treated with triplet regimen of hypomethylating agent, JAK inhibitor, and venetoclax (HMA/JAKi/Ven): A multicenter case series

Discussion

Member takes

Implication

Key Points

Cite This Study

Clinical outcomes in patients with accelerated or blast-Phase MPN treated with triplet regimen of hypomethylating agent, JAK inhibitor, and venetoclax (HMA/JAKi/Ven): A multicenter case series

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider